Proactive Investors - Run By Investors For Investors

Summit identifies possible new ways to treat hospital-acquired superbugs

Using its Discuva platform, Summit has identified genes which are essential for pathogens like MRSA to survive, information which it will use to try to develop new drug candidates
Superbugs are growing increasingly resistant to existing antibiotics

Summit Therapeutics PLC (LON:SUMM) reckons it might have found “multiple” new ways to attack and kill hospital-acquired superbugs such as MRSA.

New treatments for the ESKAPE – Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp. – pathogens are needed as they become increasingly resistant to existing antibiotics.

WATCH: Summit Therapeutics sees a bright future for its antibiotics programmes

Using its Discuva platform, Summit said it had identified genes which are essential for these pathogens to survive, information which it will use to try to develop new drug candidates.

Several of these targets are now the focus of Summit’s drug development programmes, with the platform having already discovered potential new mechanism antibiotics against them.

“At the core of our innovation is our powerful Discuva Platform,” said chief executive Glyn Edwards.

“The platform allows us to uncover possible new ways to combat the potentially deadly ESKAPE pathogens.

“We can then aim to exploit this knowledge through the discovery and development of targeted new mechanism antibiotics.”

Shares were up 2% to 38.3p in early afternoon trading.

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

scientist in a lab
April 12 2019
Danish giant Novo Nordisk recently signed up to use its NDD platform, and bosses expect more collaboration deals in the coming months
September 28 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use